Monthly Archives: September 2023

What do you think of when talking about AI in the Drug discovery and drug development process?

26th September 2023Education, Generative AI, Large Language Models, Lund Universityper

A great day with the students at the Medicinal Chemistry master program at Lund University.

A lot of thoughts and questions, and a fun and creative environment to be in.

Tech stack, Transformers and HealthTech

24th September 2023chat-GPT, Generative AI, HealthTech, Sector Convergence, Talent Attractionper

Thanks Ödgärd Andersson and Zenseact for highlight the importance of the stack. An interesting day discussing transformers, talent development and opportunities. Also, to put the lenses of HealthTech on the developments made the ways sectors convergence shine up.

World Investment Trends

20th September 2023Business Intelligence, Economics, Politicsper

https://unctad.org/publication/world-investment-report-2023

Take a look at the current investment Trends, how we highlight our strengths and opportunities within them. A good way to leverage the way we synchronize knowledge and willingness to invest.

Biotech and Business drivers

19th September 2023Economics, Ecosystem, Intellectual Property, Search & EvaluationBiotech, Businessper

A growing Medicon Village and IDEON highlights the importance of biotechnology out into a business and innovation context.

Reflecting on AI with the Life Science experts of the future

18th September 2023Education, Generative AI, Lund University, Talent Attraction, Universityper

Today I got the opportunity to talk about AI in the Drug Discovery and Development process at Lund University. Sharing a few reflections in the audience here.

Search & Evaluation and Due Diligence – in a Digital Life Science area

15th September 2023New opportunities, Search & Evaluationper

How do you map out what opportunities there are, where you can capture the Innovations from a digitally focused HealthTech company? How can the due diligence process look like? And what’s the Trend in the area of expertise?

Build for 7 years ahead

14th September 2023Business Development, Economics, Events, Innovation management, Search & Evaluationper

Start small, think big, scale fast. This can. Be applied in projects you do, or businesses you try, and in many other areas as well of course.

How to scale a biotech company from first seed to a globally reaching, growing and profitable situation, was an interesting discussion to have. In addition with the luxury to have it over a coffee and with local partners.

AI as a driver for future business models in Medtech and Pharma

13th September 2023Business Development, chat-GPT, Ecosystem, Generative AI, Intellectual Property, IT, Search & Evaluation, Talent Attractionper

A day focused on innovation, in an Healthcare setting and with the opportunities and challenges with the development of Generative Pre-trained Transformers (GPTs) and AI models behind.

Around digital health technologies. How to improve data analytics, and enhance the patient journey across the continuum of care.

Marie Curie PhD program – health data security

8th September 2023Biophysics in drug discovery, Talent Attractionper

Still with a fantastic input to science and technology, and most importantly the people working in the fields.

Take a look…

7th September 2023Innovation management, Sector Convergence, Talent Attractionper

https://www.linkedin.com/posts/azbioventurehub_growinginnovationtogether-sectorconvergence-activity-7105542114750418944-7jP5?utm_source=share&utm_medium=member_desktop

Due Diligence capabilities and development in AI in an M&A setting

7th September 2023Business Development, Business Intelligence, New opportunitiesAI, Due Diligence, M&A, Pharmaper

Due diligence is a critical process in mergers and acquisitions (M&A), ensuring that all aspects of a potential deal are thoroughly examined before finalizing the transaction. The integration of artificial intelligence (AI) into due diligence processes has significantly enhanced the capabilities and efficiency of this crucial phase.

AI-driven due diligence leverages advanced algorithms and machine learning to analyze vast amounts of data quickly and accurately. This technology can identify patterns, anomalies, and potential risks that might be overlooked by human analysts. For instance, AI can automate the review of financial statements, legal documents, and compliance records, reducing the time and effort required for manual analysis12.

Moreover, AI can enhance the accuracy of due diligence by providing deeper insights into the target company’s operations, market position, and potential synergies. It can also help in assessing the cultural fit between the merging entities by analyzing employee sentiment and organizational culture through various data sources3.

The development of AI in due diligence is ongoing, with continuous improvements in natural language processing, predictive analytics, and data visualization. These advancements enable more comprehensive and real-time analysis, allowing M&A teams to make informed decisions with greater confidence45.

In summary, the integration of AI into due diligence processes in an M&A setting offers significant benefits, including increased efficiency, accuracy, and deeper insights. As AI technology continues to evolve, its role in due diligence is expected to become even more pivotal, transforming how M&A transactions are conducted.